Compare Ascendis Pharma A/S (ASND) vs Global X Uranium ETF (URA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Global X Uranium ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Global X Uranium ETF trades at $42.22. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| ASND | URA | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $277.18 | $61.81 |
52-Week Low | $163.32 | $36.45 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
URA (Global X Uranium ETF) trades at $42.97, up 1.46% today but showing a bearish technical trend with 13 sell signals in moving averages. The fund holds $6.29 billion in assets across 56 uranium and nuclear energy companies. Recent news highlights strong thematic tailwinds from AI-driven power demand and government support for nuclear energy, positioning URA at the intersection of energy security and technology infrastructure growth.
The outlook for URA is supported by structural demand drivers but faces near-term technical weakness. Investment opportunity lies in the nuclear renaissance narrative, while risks include ETF liquidity constraints and uranium price volatility. The fund's 0.52% expense ratio is higher than broad energy ETFs, requiring sustained thematic performance to justify costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
